Recovery of urinary continence after neoadjuvant hormonal therapy plus radical prostatectomy: A multicenter...

This study aimed to evaluate the impact of neoadjuvant hormonal therapy (NHT) combined with robotic-assisted radical prostatectomy (RARP) on postoperative urinary continence (UC) recovery compared with RARP alone in patients with localized prostate cancer.

A multicenter retro-prospective cohort study was conducted involving 2453 patients treated between November 2018 and November 2023 at four tertiary hospitals in China. After applying exclusion criteria, 1927 patients who completed 1-year follow-up were included (760 NHT plus RARP and 1167 RARP alone). Propensity score matching (1:1) was performed based on age, prostate volume, body mass index, preoperative prostate-specific antigen level, surgical approach, and pT stage, resulting in 249 matched pairs. UC was defined as using no pad or one safety pad per day and assessed via standardized questionnaires during follow-up visits.

The NHT group demonstrated significantly better UC recovery compared with the control group (p<0.001). The median time to UC recovery was 8 (interquartile range: 3-24) weeks for the NHT group and 16 (interquartile range: 4-34) weeks for the control group. Short-term continence rates (range: 2-12 weeks) were significantly higher in the NHT group (42% vs. 24%, p<0.001). Multivariate Cox regression analysis identified NHT (hazard ratio 1.273, 95% confidence interval 1.063-1.525, p=0.009) and age (hazard ratio 0.968, 95% confidence interval 0.955-0.980, p<0.001) as independent predictors of UC recovery.

Preoperative NHT was associated with significantly improved postoperative UC recovery after RARP, including faster recovery time and higher short-term continence rates. These findings suggest that NHT may provide functional benefits beyond its established oncological effects in prostate cancer treatment.